Target ACE2, Spike protein

Aus coViki
(Unterschied zwischen Versionen)
Wechseln zu: Navigation, Suche
K
 
(19 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt)
Zeile 1: Zeile 1:
 
ACE2; any specific functions of spike protein;  
 
ACE2; any specific functions of spike protein;  
see also '''[[RSP - On RAS drugs]]'''
+
{{up|PHA antivirals by mechanism}}
 +
{{up|PHA pharmacophore by screened target}}
  
 +
{{qt|PHA ACE2 Structure spike-ace2}}
 +
{{qt|PHA ACE2 in target tissues}}
 +
{{qt|PHA ACE2 regulation of ACE2}}
 +
{{qt|PHA ACE2 drug design}} spike RBD
 +
{{qt|PHA SCR spike protein general aspects}} spike any target
 +
{{qt|PHA ACE2 amplification}}
 +
{{qt|PHA ACE2 soluble ace2}}
 +
{{qt|PHA Angiotensin(1-7)}}
 +
{{qt|PHA Angiotensin II}}
 +
{{qt|RSP - On RAS drugs}}
 +
{{qt|MOD ACE2 transgenic mice}}
 +
{{qt|MOD Zebrafish}}
 +
{{qt|PHA ACE2 ace2 species specificity clade specificity}}
  
'''regulation of ace2'''
 
{{tp|p=32291076|t=ä. EZH2-mediated H3K27me3 inhibits ACE2 expression |pdf=|usr=}}
 
{{tp|p=32133153|t=2020. Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations |pdf=|usr=}}
 
{{tp|p=32372801|t=2020. (ACE2) Does a cell protein explain covid-19 severity?|pdf=|usr=}}
 
{{tp|p=32302706|t=2020. Physiological and pathological regulation of ACE2, the SARS-CoV-2 receptor |pdf=|usr=}}
 
  
'''ace2 species specificity clade specificity'''
+
{{ttp|p=32449939|t=2020. SARS-CoV-2 spike glycoprotein-binding proteins expressed by upper respiratory tract bacteria may prevent severe viral infection.|pdf=|usr=007}}
{{tp|p=32092392|t=2020. Analysis of angiotensin-converting enzyme 2 (ACE2) from different species sheds some light on cross-species receptor usage of a novel coronavirus 2019-nCoV |pdf=|usr=}}
+
{{tp|p=32582574|t=2020. ACE2, Much More Than Just a Receptor for SARS-COV-2.|pdf=|usr=011}}
{{tp|p=32199943|t=ä. Predicting the angiotensin converting enzyme 2 (ACE2) utilizing capability as the receptor of SARS-CoV-2 |pdf=|usr=}}
+
{{tp|p=32738617|t=2020. ACE2 Co-evolutionary Pattern Suggests Targets for Pharmaceutical Intervention in the COVID-19 Pandemic.|pdf=|usr=018}}
{{tp|p=32100877|t=ä. Composition and divergence of coronavirus spike proteins and host ACE2 receptors  predict potential intermediate hosts of SARS?CoV?2 |pdf=|usr=}}
+
{{tp|p=32602627|t=2020. Angiotensin-converting enzyme 2: The old door for new severe acute respiratory syndrome coronavirus 2 infection.|pdf=|usr=011}}
{{tp|p=32249956|t=ä. Structural variations in human ACE2 may influence its binding with SARS?CoV?2 spike protein |pdf=|usr=}}
+
{{tp|p=32585135|t=2020. Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike.|pdf=|usr=010}}
{{tp|p=32374452|t=2020. SARS-CoV-2: Structural diversity, phylogeny, and potential animal host identification of spike glycoprotein |pdf=|usr=}}
+
{{tp|p=32747721|t=2020. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19.|pdf=|usr=018}}
{{tp|p=32239522|t=ä. SARS?CoV?2 spike protein favors ACE2 from Bovidae and Cricetidae |pdf=|usr=}}
+
{{tp|p=32913581|t=2020. Unlocking COVID therapeutic targets: A structure-based rationale against SARS-CoV-2, SARS-CoV and MERS-CoV Spike.|pdf=|usr=019}}
 
+
'''any receptors in target tissues'''
+
{{tp|p=32199615|t=ä. Single cell RNA sequencing of 13 human tissues identify cell types and receptors  of human coronaviruses |pdf=|usr=}}
+
 
+
 
+
'''ACE2 expression in target tissues'''
+
{{tp|p=32279908|t=ä. Is the ACE2 Overexpression a Risk Factor for COVID-19 Infection?|pdf=|usr=}}
+
{{tp|p=32251718|t=2020. ACE2 at the centre of COVID-19 from paucisymptomatic infections to severe pneumonia |pdf=|usr=}}
+
{{tp|p=32227090|t=ä. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2 |pdf=|usr=}}
+
{{tp|p=32364961|t=2020. Severe respiratory SARS-CoV2 infection: Does ACE2 receptor matter?|pdf=|usr=}}
+
 
+
 
+
'''Structure spike/ace2'''
+
 
+
{{tp|p=32057769|t=2020. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade |pdf=|usr=}}
+
{{tp|p=32155444|t=ä. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein |pdf=|usr=}}
+
{{tp|p=32178593|t=2020. Emerging WuHan (COVID-19) coronavirus: glycan shield and structure prediction of  spike glycoprotein and its interaction with human CD26 |pdf=|usr=}}
+
{{tp|p=32320687|t=ä. Phylogenetic Analysis and Structural Modeling of SARS-CoV-2 Spike Protein Reveals an Evolutionary Distinct and Proteolytically Sensitive Activation Loop |pdf=|usr=}}
+
{{tp|p=32009228|t=2020. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission |pdf=|usr=}}
+
{{tp|p=32075877|t=2020. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation |pdf=|usr=}}
+
{{tp|p=32081428|t=2020. Structure analysis of the receptor binding of 2019-nCoV |pdf=|usr=}}
+
{{tp|p=32142651|t=2020. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically  Proven Protease Inhibitor |pdf=|usr=}}
+
{{tp|p=32203189|t=ä. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus:  implication for development of RBD protein as a viral attachment inhibitor and vaccine |pdf=|usr=}}
+
{{tp|p=32275855|t=ä. Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2 |pdf=|usr=}}
+
{{tp|p=32201080|t=ä. Spike protein recognition of mammalian ACE2 predicts the host range and an optimized ACE2 for SARS-CoV-2 infection |pdf=|usr=}}
+
{{tp|p=32210742|t=2020. Role of changes in SARS-CoV-2 spike protein in the interaction with the human ACE2 receptor: An in silico analysis |pdf=|usr=}}
+
{{tp|p=32327200|t=ä. Covid-19 and the angiotensin-converting enzyme (ACE2): Areas for research |pdf=|usr=}}
+
{{ttp|p=32274964|t=2020. A review on the cleavage priming of the spike protein on coronavirus by angiotensin-converting enzyme-2 and furin |pdf=|usr=}}
+
{{tp|p=31996437|t=2020. Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus |pdf=|usr=}}
+
{{ttp|p=32362314|t=ä. A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells |pdf=|usr=}}
+
{{tp|p=32221306|t=2020. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV |pdf=|usr=}}
+
{{ttp|p=32150576|t=2020. Structure of mouse coronavirus spike protein complexed with receptor reveals mechanism for viral entry |pdf=|usr=}}
+
{{tp|p=32245784|t=2020. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2  and SARS-CoV |pdf=|usr=}}
+
{{ttp|p=32366695|t=ä. Site-specific glycan analysis of the SARS-CoV-2 spike |pdf=|usr=}}
+
{{tp|p=32132184|t=2020. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2 |pdf=|usr=}}
+
{{tp|p=32198713|t=ä. A Unique Protease Cleavage Site Predicted in the Spike Protein of the Novel Pneumonia Coronavirus (2019-nCoV) Potentially Related to Viral Transmissibility |pdf=|usr=}}
+
{{tp|p=32365751|t=2020. The SARS-CoV-2 Exerts a Distinctive Strategy for Interacting with the ACE2 Human  Receptor |pdf=|usr=}}
+
{{tp|p=32378705|t=2020. A virus that has gone viral: amino acid mutation in S protein of Indian isolate of Coronavirus COVID-19 might impact receptor binding, and thus, infectivity |pdf=|usr=}}
+
{{tp|p=32132669|t=2020. Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV |pdf=|usr=}}
+
{{tp|p=32338224|t=2020. Focus on Receptors for Coronaviruses with Special Reference to Angiotensin-converting Enzyme 2 as a Potential Drug Target - A Perspective |pdf=|usr=}}
+
{{tp|p=32363391|t=ä. Deducing the N- and O- glycosylation profile of the spike protein of novel coronavirus SARS-CoV-2 |pdf=|usr=}}
+
{{ttp|p=32374903|t=2020. SARS-CoV-2 viral spike G614 mutation exhibits higher case fatality rate |pdf=|usr=}}
+
{{tp|p=32376714|t=2020. Gene of the month: the 2019-nCoV/SARS-CoV-2 novel coronavirus spike protein |pdf=|usr=}}
+
{{tp|p=32225176|t=2020. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor |pdf=|usr=}}
+
{{tp|p=32225175|t=2020. Structural basis of receptor recognition by SARS-CoV-2 |pdf=|usr=}}
+
{{tp|p=32329276|t=2020.  Spike protein in the detection and treatment of novel coronavirus  |pdf=|usr=}}
+
{{tp|p=C7190498|t=ä. The biological characteristics of SARS-CoV-2 spike protein Pro330-Leu650 |pdf=|usr=}}
+
 
+
'''Drug design'''
+
 
+
{{ttp|p=C7151553|t=2020. COVID-19 Coronavirus spike protein analysis for synthetic vaccines, a peptidomimetic antagonist, and therapeutic drugs, and analysis of a proposed achilles? heel conserved region to minimize probability of escape mutations and drug resistance |pdf=|usr=}}
+
{{tp|p=32286790|t=ä. Computational Design of ACE2-Based Peptide Inhibitors of SARS-CoV-2 |pdf=|usr=}}
+
{{tp|p=32333836|t=ä. Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2 |pdf=|usr=}}
+
{{tp|p=32125455|t=ä. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target |pdf=|usr=}}
+
{{tp|p=32231345|t=2020. Inhibition of SARS-CoV-2 (previously 2019-nCoV)infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high  capacity to mediate membrane fusion |pdf=|usr=}}
+
{{tp|p=32354636|t=ä. Blockade of SARS-CoV-2 infection by recombinant soluble ACE2 |pdf=|usr=}}
+
{{tp|p=32332922|t=ä. SARS-CoV-2 infection of kidney organoids prevented with soluble human ACE2 |pdf=|usr=}}
+
{{tp|p=32294562|t=ä. A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease |pdf=|usr=}}
+
{{tp|p=32359080|t=2020. Off-target ACE2 ligands: Possible therapeutic option for CoVid-19?|pdf=|usr=}}
+
{{tp|p=32167153|t=2020. Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?|pdf=|usr=}}
+
{{tp|p=32373991|t=2020. In silico screening of natural compounds against COVID-19 by targeting Mpro and ACE2 using molecular docking |pdf=|usr=}}
+
{{tp|p=32232976|t=2020. CD-sACE2 inclusion compounds: An effective treatment for coronavirus disease 2019 (COVID-19) |pdf=|usr=}}
+
{{tp|p=32362217|t=2020. In silico study the inhibition of angiotensin converting enzyme 2 receptor of COVID-19 by Ammoides verticillata components harvested from Western Algeria |pdf=|usr=}}
+
{{tp|p=32345124|t=2020. An in-silico evaluation of different Saikosaponins for their potency against SARS-CoV-2 using NSP15 and fusion spike glycoprotein as targets |pdf=|usr=}}
+
{{tp|p=32379346|t=2020. ACE2 Activators for the Treatment of Covid 19 Patients |pdf=|usr=}}
+
{{tp|p=32332765|t=2020. Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig |pdf=|usr=}}
+
{{tp|p=32376627|t=2020. Design of potent membrane fusion inhibitors against SARS-CoV-2, an emerging coronavirus with high fusogenic activity |pdf=|usr=}}
+
{{tp|p=32380200|t=ä. In Silico Design of Antiviral Peptides Targeting the Spike Protein of SARS-CoV-2 |pdf=|usr=}}
+
{{ttp|p=C7197610|t=ä. Isolation of a human monoclonal antibody specific for the receptor binding domain of SARS-CoV-2 using a competitive phage biopanning strategy |pdf=|usr=}}
+
{{ttp|p=32231345|t=ä. Inhibition of SARS-CoV-2 infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high  capacity to mediate membrane fusion |pdf=|usr=}}''Here we generated a series of lipopeptides derived from EK1 and found that EK1C4 was the most potent fusion inhibitor against SARS-CoV-2 S protein-mediated membrane fusion and pseudovirus infection''
+
{{tp|p=32336762|t=2012. Design of Angiotensin?converting Enzyme 2 (ACE2) Inhibitors by Virtual Lead Optimization and Screening |pdf=|usr=}}
+
{{tp|p=32380200|t=2020. In silico design of antiviral peptides targeting the spike protein of SARS-CoV-2 |pdf=|usr=}}
+
{{tp|p=32065055|t=2020. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody |pdf=|usr=}}
+
{{tp|p=32285293|t=ä. Searching therapeutic strategy of new coronavirus pneumonia from angiotensin-converting enzyme 2: the target of COVID-19 and SARS-CoV |pdf=|usr=}}
+
{{tp|p=32313207|t=ä. Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor |pdf=|usr=}}
+
{{tp|p=32346094|t=ä. COVID-19 vaccine design: the Janus face of immune enhancement |pdf=|usr=}}
+
{{tp|p=32369402|t=2020. ANNALS EXPRESS: Coronavirus disease 2019 (COVID-19) and the renin-angiotensin system: a closer look at angiotensin-converting enzyme 2 (ACE2) |pdf=|usr=}}
+
{{tp|p=32354022|t=2020. ACE2: The key Molecule for Understanding the Pathophysiology of Severe and Critical Conditions of COVID-19: Demon or Angel?|pdf=|usr=}}
+
{{tp|p=32306452|t=2020. Angiotensin-converting enzyme 2 in severe acute respiratory syndrome coronavirus  and SARS-CoV-2: A double-edged sword?|pdf=|usr=}}
+
{{tp|p=32451080|t=ä. A possible strategy to fight COVID-19: Interfering with spike glycoprotein trimerization |pdf=|usr=}}
+

Aktuelle Version vom 27. April 2021, 19:39 Uhr

ACE2; any specific functions of spike protein;

PHA antivirals by mechanism
PHA pharmacophore by screened target
PHA ACE2 Structure spike-ace2
PHA ACE2 in target tissues
PHA ACE2 regulation of ACE2
PHA ACE2 drug design
spike RBD
PHA SCR spike protein general aspects
spike any target
PHA ACE2 amplification
PHA ACE2 soluble ace2
PHA Angiotensin(1-7)
PHA Angiotensin II
RSP - On RAS drugs
MOD ACE2 transgenic mice
MOD Zebrafish
PHA ACE2 ace2 species specificity clade specificity


32449939 2020. SARS-CoV-2 spike glycoprotein-binding proteins expressed by upper respiratory tract bacteria may prevent severe viral infection.


32582574 2020. ACE2, Much More Than Just a Receptor for SARS-COV-2.
32738617 2020. ACE2 Co-evolutionary Pattern Suggests Targets for Pharmaceutical Intervention in the COVID-19 Pandemic.
32602627 2020. Angiotensin-converting enzyme 2: The old door for new severe acute respiratory syndrome coronavirus 2 infection.
32585135 2020. Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike.
32747721 2020. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19.
32913581 2020. Unlocking COVID therapeutic targets: A structure-based rationale against SARS-CoV-2, SARS-CoV and MERS-CoV Spike.

Meine Werkzeuge
Namensräume
Varianten
Aktionen
Navigation
Werkzeuge
Blogverzeichnis - Blog Verzeichnis bloggerei.deBlogverzeichnis